ArticleFrontiers in medicine2026
Glucose-6-phosphate dehydrogenase deficiency and the risk of developing systemic lupus erythematosus.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the relationship between glucose-6-phosphate dehydrogenase (G6PD) deficiency and the risk of developing systemic lupus erythematosus (SLE). Methods: A case-control study was conducted including 516 female SLE patients (SLE group) and 491 age-matched healthy females (control group) from August 2023 to August 2024. G6PD enzymatic activity was detected via the G6PD/6PGD ratio method, and G6PD gene mutations were identified by PCR combined with flow hybridization; 21 G6PD-deficient samples underwent whole-exome sequencing (WES) for genotype verification. The two groups were stratified by enzymatic status, and differences in enzymatic ratios, gene mutation rates and mutation types were compared using rank-sum test and Pearson's chi-square test with SPSS 25.0. Results: The G6PD enzymatic deficiency rates were 9.69% (50/516) in the SLE group and 10.79% (53/491) in the control group ( Conclusion: G6PD deficiency does not correlate with the risk of developing systemic lupus erythematosus. Funding project: Yangjiang High-level Key Medical and Health Research Project (2023001).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.